Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Portfolio Pulse from
Instil Bio has released its financial results for Q4 and the full year 2024, along with a corporate update. The company is anticipating clinical data for AXN-2510/IMM2510 monotherapy in relapsed/refractory NSCLC in China by ImmuneOnco, as well as additional safety data in other solid tumors, in the first half of 2025.
March 04, 2025 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Instil Bio has announced its Q4 and full year 2024 financial results. The company is also expecting important clinical data for its AXN-2510/IMM2510 monotherapy in NSCLC by mid-2025.
The financial results provide a snapshot of the company's performance, which is crucial for investors. The anticipation of clinical data for AXN-2510/IMM2510 is significant for future growth prospects, but the impact is neutral in the short term as the data is expected in 2025.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80